Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

organic photoconductor drum coatings manufacturing operations in Shanghai - $8 million; -- Digital detectors supplied to an OEM - $8 million; -- Molecular tests no longer marketed as an analyte specific reagent (ASR) - $5 million. -- The Company expects EPS to be approximately $0.42 to $0.46 and non-GAAP adjusted EPS to be approximately $1.15 to $1.19.

A reconciliation of the Company's GAAP to non-GAAP fiscal 2010 projections is included as an attachment to this press release.

Hologic may incur expenses or charges or realize income or gains in fiscal 2010 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S. and general worldwide economic and regulatory conditions and related uncertainties, including proposed healthcare reform and associated tax proposals, which, along with other uncertainties facing our business, could adversely affect anticipated results.

Conference Call and Webcast:

Hologic's management will host a conference call on Monday, November 9, 2009, at 5:00 p.m. (EST) to discuss fourth quarter and fiscal 2009 operating results. Interested participants may listen to the call by dialing 877-719-9786 or 719-325-4786 for international callers and referencing access code 9714531 approximately 15 minutes prior to the call. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, November 20, 2009, at 888-203-1112 or 719-457-0820 for international callers, access code 9714531. The Company will also provide a live webcast and archive of the call on the investor relations page of the Company's website at www.hologic.com/investor. A replay of the call will also be archived on this same website. A PowerPoint presentation related to the conference call will be po
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
(Date:3/4/2015)... 4, 2015 Following the reintroduction of ... Center (LAC) released a report today urging policymakers ... and heroin epidemic through more effective use of ... "The Case for Expanding Access to Medication-Assisted Treatment ... the health, justice, and economic advantages of medication-assisted ...
(Date:3/4/2015)... 2015  Heska Corporation (Nasdaq: HSKA ) ... Join Its Fourth Quarter and Year End 2014 Earnings ... 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: www.heska.com ... Call link on the front page of this website)How:Live ... web at the address above.  Alternatively, you may use ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... , MELVILLE, N.Y. , Jan. 25 ... provider of health care products and services to office-based practitioners, announced today ... and Chief Financial Officer, will present at the Jefferies 2010 Global Healthcare ... Schein,s presentation is scheduled to begin at 3:30 p.m. EST ...
... , , RYE, N.Y. , ... a drug research and development company focused on the treatment of neurological ... clinical trials for CM-AT, its autism treatment, at ten sites across the ... New York City Drexel University , Philadelphia ...
Cached Medicine Technology:Henry Schein To Present At The Jefferies 2010 Global Healthcare Services Conference 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 04, 2015 " Optrix by Body ... its monthly Tech Report, which takes a look at ... to consumers. Scott Steinberg, a special reporter for NewsWatch ... shared with viewers how they have an ultra-rugged, waterproof ... industry is a major player at the Consumer Electronics ...
(Date:3/4/2015)... March 04, 2015 The Global ... billion in 2014 and is estimated to grow ... of 4.0% from 2014 to 2019. , Browse ... Market for an analysis of industry trends, segments ... global liquefied petroleum gas market is classified into ...
(Date:3/4/2015)... Organic Valley, the nation’s largest cooperative of ... cause campaign to Save the Bros, http://savethebros.com/ with ... difference to Bros everywhere. To date, the video has ... The video was named Adweek’s best commercial of the week ... Digiday, among other media outlets. , “We are pleased ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , , IRVINE, Calif., Aug. ... share of $0.49 for the quarter ended June 30, 2009, a 24% ... The Company reported quarterly revenues of $81 million, a 4% increase compared ... , The Company,s results are reflective of improved growth ...
... an increased risk of death, found a new study of ... in CMAJ ( Canadian Medical Association Journal ) ... approximately 25% of people (both men and women) living in ... develop a spine fracture will die over a 5 year ...
... ... their already booming empire of top physicians. The much awaited International Association of Dermatologists ... their renowned directory, "The Leading Physicians Of the World". , ... New York, NY (PRWEB) August 3, 2009 ...
... , , CHICAGO, Aug. 3 Eczema ... rashes. It is commonly known as "the itch that rashes." (1) ... appears to result from a complex interaction of factors including personal and ... Scratching the affected area can lead to more itch, redness, swelling, ...
... Commentary by Betsy McCaughey ,rife with gross, cruel distortions, ... York State Director Lois Aronstein issued the following statement in response to ... reform measures passed or currently being considered by Congress. , , ... various media outlets is rife with gross -- and even cruel -- ...
... , , , ... N.C., Aug. 3 Kowa Research Institute (KRI) based in ... specialty pharmaceutical company headquartered in Montgomery, AL, announced today that ... (R) (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for ...
Cached Medicine News:Health News:CorVel Announces Revenues and Earnings 2Health News:CorVel Announces Revenues and Earnings 3Health News:CorVel Announces Revenues and Earnings 4Health News:CorVel Announces Revenues and Earnings 5Health News:Hip and back fractures increase mortality rates in people older than 50 2Health News:Top Dermatologists to be Selected and Published in "The Leading Physicians of the World" Consumer Directory. 2Health News:Five Questions About Eczema 2Health News:Five Questions About Eczema 3Health News:Five Questions About Eczema 4Health News:Five Questions About Eczema 5Health News:AARP Responds to Health Reform Scare Tactics 2Health News:AARP Responds to Health Reform Scare Tactics 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 2Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 4
The Medtronic EOPA CAP® arterial cannula provides a simple solution to obtaining accurate arterial pressure readings....
Intermittent catheter...
Intermittent catheter...
... new dimension in vitreoretinal surgery. ,By ... of purified perfluoro-n-octane, you can greatly ... ideal for managing retinal detachments complicated ... and trauma. , ,Certified to be ...
Medicine Products: